Los Angeles, California 90048


Purpose:

The purpose of this study is to test the effect of long-acting somatostatin analog medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in comparison to healthy controls who are not receiving the medication in order to see whether or not the medication makes the oral glucose test less accurate. The Oral Glucose Tolerance Test (OGTT) is a standard test to measure growth hormone secretion. By comparing GH responses in non-acromegaly subjects taking somatostatin analog treatment, the relative contribution of the medication and the underlying disease state can be analyzed.


Study summary:

Subjects will be informed of the study and after providing written informed consent, subjects will be asked to undergo a 2-hour oral glucose tolerance test (ingestion of 75g glucose with subsequent timed assessment of growth hormone, glucose, insulin and related binding proteins.) Baseline assessment of hormones that may contribute to the results will be drawn, prior to performing the test. Patients will be asked to complete one visit total to participate in this trial.


Criteria:

Inclusion Criteria: - Diagnosis of acromegaly or carcinoid syndrome - Treatment with somatostatin analog therapy (must have established a stable dose of three or more injections on the same dose prior to study enrollment) - Healthy control subjects Exclusion Criteria: - Diagnosis of Diabetes Mellitus (Type 1 or Type 2) - Use of medication for the treatment of insulin resistance or diabetes


NCT ID:

NCT01371045


Primary Contact:

Principal Investigator
John D Carmichael, M.D.
Cedars-Sinai Medical Center

Hershel Bhadsavle
Phone: (310) 423-2830
Email: hershel.bhadsavle@cshs.org


Backup Contact:

Email: Billy.Gellepis@cshs.org
Billy Gellepis
Phone: 310-423-3395


Location Contact:

Los Angeles, California 90048
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.